From Yahoo Finance: 2025-04-25 13:45:00

Merck KGaA is in late-stage negotiations for a potential $3.5bn deal with SpringWorks, at an estimated price of $47 per share. The acquisition would strengthen Merck KGaA’s oncology portfolio with SpringWorks’ approved therapies and promising pipeline. SpringWorks shares surged 34% in response, with projections of significant sales growth for the acquired products.

The deal, which has been in discussion since February, could value SpringWorks at around $3.5bn. Merck KGaA’s CEO has been tight-lipped about the negotiations, keeping investors intrigued. Shares in SpringWorks rose nearly 9% after the latest update, indicating market optimism about the potential acquisition.

SpringWorks’ approved therapies, including Ogsiveo and Gomekli, have significant sales potential, with forecasts projecting revenues in the billions by 2030. This deal could significantly enhance Merck KGaA’s position in the oncology market, complementing its existing portfolio led by top-selling product Erbitux.

Merck KGaA’s focus on expanding its oncology portfolio is evident with recent collaborations and internal ADC programme progress. The company’s strategic moves underscore its commitment to innovation and growth in the competitive pharmaceutical landscape. The potential acquisition of SpringWorks aligns with Merck KGaA’s long-term vision and market positioning.



Read more at Yahoo Finance: Merck KGaA nears $3.5bn deal for SpringWorks